Uji Klinis

01Overview and Rationale

Before any drug can be prescribed to patients, it must undergo a rigorous evaluation pipeline. The clinical trial system exists to answer three fundamental questions in sequence: Is it safe?, Does it work?, and Is it better than what we already have?

The entire process, from preclinical testing through Phase IV surveillance, typically spans 10 to 15 years and involves progressively larger populations. The logic is straightforward: you first test in a small number of healthy volunteers to establish safety, then expand to patients with the target disease to establish efficacy, and finally test in a large population to confirm the benefit-risk ratio before approval.

A critical concept for exam purposes is the Investigational New Drug (IND) application. This document compiles all preclinical data (animal pharmacology, toxicology, manufacturing details) and must be submitted to the regulatory agency before any human testing begins. If the agency does not reject the IND within 30 days, the sponsor may proceed to Phase I.

Informed consent is required from every participant in every phase. The consent process must clearly explain the experimental nature of the intervention, potential risks, the right to withdraw at any time, and any financial compensation.

02Phases of Clinical Trials

Preclinical Phase

Before any human receives an experimental compound, the drug must be tested in in vitro (cell cultures, tissue samples) and in vivo (animal models) systems. The goals are to determine basic pharmacodynamics (what the drug does to the body), pharmacokinetics (what the body does to the drug), and acute toxicity profiles.

Animal models are selected based on biological similarity to human physiology for the organ system being targeted. For example, cardiac drugs often use canine or porcine models because of similarities in cardiac conduction.

Exam-relevant point: The preclinical phase is where the therapeutic index is first estimated. The therapeutic index is the ratio of the toxic dose to the therapeutic dose ($TI=T{D}_{50}\mathrm{/}E{D}_{50}TI\; =\; TD\_\{50\}/ED\_\{50\}$). A narrow therapeutic index means the margin between a helpful dose and a harmful dose is small, which becomes critically important in Phase I dose-escalation.

Phase 0 (Exploratory IND / Microdosing)

Phase 0 is a relatively newer addition to the trial framework. It involves administering sub-therapeutic doses (typically less than 1% of the pharmacologically active dose) to a very small number of healthy volunteers (10-15 subjects).

The purpose is purely exploratory: to determine whether the drug behaves in humans the way preclinical models predicted. It provides early pharmacokinetic and pharmacodynamic data without exposing participants to therapeutic-level risks.

Phase 0 does not assess safety or efficacy. It is not required by regulatory agencies and is not part of every drug development program. It exists to help sponsors make early go/no-go decisions before committing to the expense of Phase I.

Phase I: Safety and Dosing

Phase I is the first-in-human study. The drug is given to a small group of healthy volunteers with the primary aim of assessing safety, not therapeutic benefit.

The study typically uses a dose-escalation design: the first cohort receives a low dose, and if no unacceptable toxicity is observed, the next cohort receives a higher dose. This continues until the Maximum Tolerated Dose (MTD) is identified, which is the highest dose that does not cause unacceptable side effects.

Pharmacokinetic parameters measured in Phase I include absorption, distribution, metabolism, and excretion (ADME). The half-life of the drug is determined here, which guides dosing intervals for subsequent phases.

The oncology exception is a high-yield exam fact. In cancer trials, Phase I participants are typically patients with advanced or refractory disease rather than healthy volunteers, because the expected toxicity of cytotoxic agents makes it unethical to expose healthy individuals.

Approximately 70% of drugs that enter Phase I proceed to Phase II.

Phase II: Efficacy and Dose Optimization

Phase II is the first time the drug is given to patients who actually have the disease being targeted. The question shifts from "Is it safe?" to "Does it work?"

Phase II is often subdivided:

• Phase IIA focuses on dosing requirements (dose-finding studies)

• Phase IIB focuses on preliminary efficacy (proof of concept)

This is where the concept of clinical equipoise becomes important. A trial is ethical only when there is genuine uncertainty about whether the experimental treatment is better than the comparator. If preclinical data overwhelmingly favor the new drug, withholding it via a placebo arm raises ethical concerns.

Randomization is typically introduced in Phase II. Subjects are randomly assigned to treatment or control groups to minimize selection bias. Blinding (single or double) may also be introduced to reduce observer and subject bias.

About 33% of drugs that enter Phase II proceed to Phase III. Phase II has the highest attrition rate in the entire pipeline, primarily because many drugs that are safe turn out not to be sufficiently effective.

Phase III: Confirmatory Trial

Phase III is the pivotal trial that determines whether the drug will be approved. The sample size is large enough to detect clinically meaningful differences in efficacy and to identify adverse effects that may not have appeared in smaller Phase II populations.

Randomized Controlled Trials (RCTs) are the gold standard design for Phase III. The double-blind design, where neither the investigator nor the participant knows who receives the active drug versus placebo, is the strongest method for reducing bias.

Key statistical concepts tested in relation to Phase III include:

• Power analysis: The study must be adequately powered (typically 80% or greater) to detect a true treatment effect. Underpowered studies risk Type II errors (false negatives).

• Intention-to-treat (ITT) analysis: All randomized participants are included in the analysis regardless of whether they completed the protocol. This preserves the benefits of randomization and reflects real-world effectiveness.

• Per-protocol analysis: Only participants who completed the study as designed are analyzed. This reflects the drug's efficacy under ideal conditions.

Interim analysis with a Data Safety Monitoring Board (DSMB) is standard in Phase III. The DSMB reviews accumulating data at prespecified intervals and can recommend early termination if the treatment shows either overwhelming benefit (making it unethical to continue the placebo arm) or unacceptable harm.

Upon successful completion of Phase III, the sponsor submits a New Drug Application (NDA) or Biologics License Application (BLA) to the regulatory agency. The agency review period is typically 6-10 months but can be expedited through pathways such as Priority Review, Breakthrough Therapy Designation, or Accelerated Approval.

Approximately 25-30% of drugs that enter Phase III receive regulatory approval.

Phase IV: Post-Marketing Surveillance

Phase IV begins after the drug is approved and available for prescription. The purpose is pharmacovigilance: ongoing monitoring for adverse effects that were too rare or too slow to emerge during Phase III.

The rationale is mathematical. A Phase III trial of 3,000 patients will reliably detect adverse events occurring at a rate of approximately 1 in 1,000. An adverse event occurring at 1 in 10,000 or 1 in 50,000 will likely be missed until the drug is used by a much larger population.

Voluntary adverse event reporting systems (such as the FDA's MedWatch or BPOM's pharmacovigilance system) are a cornerstone of Phase IV. Healthcare providers and patients are encouraged to report suspected adverse drug reactions.

If Phase IV surveillance reveals unacceptable safety concerns, the regulatory agency may issue a Black Box Warning (the most serious warning placed on a drug label) or withdraw the drug from the market entirely. Classic examples include the withdrawal of rofecoxib (Vioxx) due to cardiovascular events and the withdrawal of thalidomide for teratogenicity.

03Key Regulatory and Ethical Concepts

04Expedited Regulatory Pathways

An important distinction: Accelerated Approval uses a surrogate endpoint rather than a direct clinical outcome. For example, a cancer drug might receive accelerated approval based on tumor shrinkage (surrogate) rather than overall survival (clinical outcome). The sponsor is then required to conduct confirmatory Phase IV trials demonstrating actual clinical benefit. If these trials fail, the approval can be withdrawn.

05Differential Concepts and Distractors

06Traps and High-Yield Pearls

The single most common trap on this topic is confusing which phase answers which question. Students frequently mix up Phase I (safety) with Phase II (efficacy) because both involve relatively small sample sizes. The discriminator is always the population: healthy volunteers in Phase I, patients with the disease in Phase II (with the oncology exception for Phase I).

A second common mistake is assuming that Phase III approval means the drug is definitively safe. Phase III trials are powered to detect common adverse effects, but rare events (occurring in fewer than 1 in 1,000 patients) will almost always escape detection until Phase IV post-marketing surveillance. When a vignette describes a drug withdrawn from the market due to a rare but serious adverse effect discovered after approval, the answer is Phase IV.

A third trap involves the analysis method. When a vignette describes a trial where many patients dropped out, and asks which analysis method best preserves the validity of randomization, the answer is intention-to-treat. Per-protocol analysis, while it may show a cleaner treatment effect, introduces attrition bias because the reasons people drop out are rarely random.

Finally, students frequently confuse the expedited pathways. The core competency being tested is whether the student can match the correct pathway to the correct scenario. A question describing a drug for a rare pediatric cancer that shows dramatic improvement in a Phase II trial compared to existing therapies is pointing toward Breakthrough Therapy Designation, not Fast Track.

The overarching principle: each phase builds on the one before it, sample sizes increase progressively, and the burden of proof shifts from "not harmful" to "demonstrably beneficial in the real world."